Byram W. Bridle
Associate Professor | PhD
Profile
Dr. Bridle is a viral immunologist who is passionate about improving life through two avenues of research. One arm of his research program is dedicated to designing and optimizing novel biotherapies for the treatment of cancers. The goal of his research team is to harness the natural power of a patient's immune system to eliminate their own cancer cells. This represents the ultimate personalized therapy and holds the potential to treat cancers more effectively, safely, and at lower cost than current options. The second arm of his research program focuses on studying host responses to viruses and other inflammatory stimuli. This has implications for the treatment of infectious diseases and inflammation-mediated disorders. These two programs have been unified in a unique way. The Bridle lab is harnessing their expertise in making potent cancer vaccines and combining this with their interest in anti-viral immunity to develop vaccines to protect against infectious diseases such as those caused by highly pathogenic coronaviruses. Mentoring the next generation of Canadian scientists is a responsibility that Dr. Bridle takes very seriously. He also counts it a privilege to teach students in the Doctor of Veterinary Medicine, graduate and undergraduate programs at the University of Guelph.
https://ovc.uoguelph.ca/pathobiology/people.../Byram-W-BridleВетеринары разные бывают.
The research program in the Bridle lab has two arms. One is to develop novel, highly targeted biotherapies for the treatment of cancers. In an effort to kill malignant cells with minimal bystander damage to normal tissues, two approaches are combined: (a) cancer immunotherapy that directs the power of a patient’s immune system against their own tumour(s) and, (B) oncolytic virotherapy, which utilizes viruses that replicate in and kill only cancerous cells. The exquisite specificity, systemic targeting capability and short treatment windows of these therapies hold promise that cancer patients might be effectively treated with reduced side-effects and at minimal cost. The goal is to translate the most promising iterations of these therapies into clinical trials in companion animals as a stepping stone towards testing in human patients. A second emphasis of the lab is the study of host responses to viruses. An area of focus is developing a better understanding of the mechanisms underlying virus-induced cytokine storms. Dr. Bridle's research team has identified a critical role of signaling through the type I interferon receptor in the negative regulation of an extensive network of cytokines. Cytokine responses to viruses are often very different between females and males and the Bridle lab group is seeking to understand why. At the intersection of these two programs, is a research initiative aimed at modifying the research team's optimized cancer vaccine platforms to target severe acute respiratory syndrome coronavirus (SARS-CoV)-2, which is the causative agent of the coronavirus disease identified at the end of 2019 (COVID-19). The long-term goal is to have a flexible technological platform to rapidly develop vaccines against highly pathogenic coronaviruses that may emerge in the future.
============
Дай ка я Гогсону грубость скажу:
Гогсон, ты дурак или придуряешься?